Effectiveness of a VAP Prevention Bundle in the PICU
Effectiveness of a Bundle of Ventilator Associated Pneumonia (VAP) Prevention in the Pediatric Intensive Care Unit (PICU): an Observational Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Orazio Genovese, MD
- Phone Number: 0630153125
- Email: orazio.genovese@policlinicogemelli.it
Study Locations
-
-
RM
-
Roma, RM, Italy, 00168
- Recruiting
- Fondazione Policlinico Universitario Agostino Gemelli
-
Contact:
- Orazio Genovese, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- age < 18 years
- patients receiving mechanical ventilation for more than 48 hours
Exclusion Criteria:
- no informed consent
- pregnancy
- previous endotracheal antibiotic therapy
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Retrospective control group
Patients admitted in our PICU before the implementation of the protocol for VAP prevention (from 01/01/2016 to 12/31/2017)
|
evaluation of VAP incidence in our pediatric population of intensive care patients before the implementation of the protocol for VAP prevention
|
|
Prospective group
Patients admitted to our PICU since the VAP bundle has been introduced in the clinical practice (from 01/01/2018)
|
Oral hygiene care (i.e chlorhexidine swab); clean and dry ventilator circuits; head positioning at 45 degrees.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
VAP incidence
Time Frame: From 48 hours after intubation to 48 hours after extubation
|
Incidence of VAP in pediatric patients intubated for more than 48 hours
|
From 48 hours after intubation to 48 hours after extubation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prevalence of orotracheal bacterial colonization in ventilated patients
Time Frame: From 48 hours after intubation to 48 hours after extubation
|
Evaluation of orotracheal bacterial colonization in pediatric patients undergoing mechanical ventilation twice a week
|
From 48 hours after intubation to 48 hours after extubation
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Giorgio Conti, MD, Università Cattolica del Sacro Cuore; Fondazione Policlinico Universitario Agostino Gemelli; IRCCS
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1855
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.